About this approach
An antibody-drug conjugate links a laboratory-made antibody to an anticancer drug. The antibody recognizes a target on cancer cells and helps deliver the drug payload. Treatment choice depends on the cancer, biomarker expression, prior therapy, and the specific ADC; the medicines are not interchangeable.
Where it fits: Targeted medicines that carry a drug payload to selected cancer cells
Where this treatment is used
ADCs are established in selected breast, bladder, lung, stomach, blood, and other cancers. Each product has its own approved indication and supporting evidence.
Procedure and practical considerations
Risks vary by ADC and can include low blood counts, nausea, fatigue, nerve damage, eye problems, liver effects, and serious lung inflammation. The antibody target does not prevent all effects on healthy tissue. Monitoring and dose changes must follow the product-specific plan.
Clinics reporting this approach
These clinic profiles mention this approach in their published materials. Open a profile to compare locations, services, practical details, and ways to get started.
Sources
Source information checked: 2026-10-07. The links below identify the public and clinic-provided materials used for this page.
Compiled by: Cancer Clinic Finder Editorial Team
- NCI Dictionary: antibody-drug conjugate ↗Checked 2026-10-07
- NCI: Advances in Breast Cancer Research ↗Checked 2026-10-07
How Cancer Clinic Finder compiles information · Suggest a factual correction
